Man dies after heavy weight-training chain around neck pulls him into MRI machine
The man, 61, had entered an MRI room while a scan was underway Wednesday afternoon at Nassau Open MRI. The machine's strong magnetic force drew him in by the metallic chain around his neck, according to a release from the Nassau County Police Department.
He died Thursday afternoon, but a police officer who answered the phone at the Nassau County police precinct where the MRI facility is located said the department had not yet been given permission to release the name Saturday.
Adrienne Jones-McAllister told News 12 Long Island in a recorded interview that she was undergoing an MRI on her knee when she asked the technician to get her husband, Keith McAllister, to help her get off the table. She said she called out to him.
She told News 12 that the technician summoned into the room her husband, who was wearing a 20-pound chain that he uses for weight training, an object they'd had a casual conversation about during a previous visit with comments like: 'Ooooooh, that's a big chain!'
When he got close to her, she said, 'at that instant, the machine switched him around, pulled him in and he hit the MRI.'
'I said: 'Could you turn off the machine, call 911, do something, Turn this damn thing off!'' she recalled, as tears ran down her face. 'He went limp in my arms.'
She said the technician helped her try to pull her husband off the machine but it was impossible.
'He waved goodbye to me and then his whole body went limp,' Jones-McAllister told the TV outlet.
Jones-McAllister told News 12 that McAllister suffered heart attacks after he was freed from the MRI machine.
A person who answered the phone at Nassau Open MRI on Long Island declined to comment Friday. The phone number went unanswered on Saturday.
It wasn't the first New York death to result from an MRI machine.
In 2001, 6-year-old Michael Colombini of Croton-on-Hudson was killed at the Westchester Medical Center when an oxygen tank flew into the chamber, drawn in by the MRI's 10-ton electromagnet.
In 2010, records filed in Westchester County revealed that the family settled a lawsuit for $2.9 million.
MRI machines 'employ a strong magnetic field' that 'exerts very powerful forces on objects of iron, some steels, and other magnetizable objects,' according to the National Institute of Biomedical Imaging and Bioengineering, which says the units are 'strong enough to fling a wheelchair across the room.'
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Analysts Are Cutting Their Price Targets for UnitedHealth Stock Before Q2 Earnings. Is It Time to Ditch Shares?
UnitedHealth (UNH) has not had a healthy time for the better part of the last 12 months. The company has been rocked by the assassination of its CEO Brian Thompson in December 2024, as well as by the questioning of its policy practices, shareholder lawsuits, and Justice Department investigations. UNH shares are now down 44% on a year to date basis. To compound matters further, analysts have been slashing their price target ahead of its second quarter earnings. Morgan Stanley's Erin Wright cut the price target from to $342 from $374 earlier, citing ongoing challenges at UnitedHealth's health services unit, Optum, and Wolfe Research trimmed its price target sharply to $330 from $363, warning about near-term earnings volatility and delayed sentiment recovery around the stock. Meanwhile, Barclays lowered its price target to $337 from $350, highlighting earnings pressure. All retained their 'Buy' or 'Outperform' ratings on the stock, though. More News from Barchart It's Never 'Happened in the History of Tech to Any Company Before': OpenAI's Sam Altman Says ChatGPT is Growing at an Unprecedented Rate This Penny Stock Wants to Become the MicroStrategy of Dogecoin Option Volatility And Earnings Report For July 21 - 25 Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! About UnitedHealth Stock Over the past 20 years, the UNH stock has been a bona fide wealth creator for its shareholders, amassing share price growth of a whopping 450%. The company now operates through two segments, UnitedHealthcare and Optum. While UnitedHealthcare offers health insurance plans, including Medicare Advantage and commercial products, Optum is a fast-growing services arm providing pharmacy benefits, care delivery, analytics, and IT services. Additionally, it is the largest health insurer in the United States and ranked number one globally by revenue in the healthcare industry. So, can UNH finally find its mojo back? I think it can and here's why. UNH Is Too Big to Ignore As highlighted above, UnitedHealth commands a dominant position as the largest health insurer in the United States. That scale gives it real leverage in the market. But perhaps more important is how the company brings together two traditionally separate lines of business. UnitedHealth commands a level of coordination that pure-play insurers can't match, allowing for operational synergies that offer both efficiency and flexibility. In the first quarter of 2025, customer growth in UnitedHealthcare was particularly notable, rising by 780,000 individuals from the previous quarter. The total number now stands at 3.2 million. This uptick appears to be linked to strong uptake in some of the company's more tailored healthcare offerings. The benefits of that growth are evident in the top-line momentum across all key business segments, including Optum Insight and Optum Rx. Delving further into Optum, what makes the business even more interesting is its steady, contract-based revenue. Unlike insurance, which tends to be vulnerable to short-term medical cost volatility, Optum offers stability. At this point, nearly 43% of UnitedHealth's operating income is being generated by its healthcare services division. And management has signaled clear intent to keep expanding this business. In 2025, they are aiming to add another 650,000 patients under value-based care agreements. Broadly, demographic forces remain in UnitedHealth's favor. As the U.S. population ages, the demand for integrated health solutions continues to rise. The company's holistic model is well suited to meet that growing demand. Still, there are concerns. UnitedHealth has been criticized for what some see as an unusually high claims denial rate, and that narrative could hurt its brand image with the possibility of consumers taking their business elsewhere. At the same time, financial ratios show pressure. The company's combined ratio sits at 97.2%, which leaves little room for error. Also, in the first quarter, its medical care ratio came in at 84.8%, a slight increase from 84.3% a year earlier. That movement, though small, is negative for profitability since it indicates that the cost of providing care is rising faster than premiums. Solid Fundamentals UnitedHealth missed both revenue and earnings estimates in the most recent quarter. Still, the company reported revenues of $109.6 billion in Q1, 2025, up $9.8 billion year over year. In terms of segments, Optum's revenues were at $63.9 billion in the quarter, up from $61.1 billion, with an improvement in operating margins to 6.1% from 5.8%, in the year-ago period. Earnings at $7.20 per share grew by 4.2% from the prior year but slightly missed the consensus estimate. Coming to cash flows, in Q1 2025, UNH's cash flow from operations surged to $5.5 billion compared to just $1.1 billion in the prior year as the company closed the quarter with a cash balance of $34.3 billion. This was much higher than its short-term debt of $9.9 billion. However, a reduction in projected 2025 net earnings per share to be between $24.65 to $25.15 per share earlier is a concern. Yet, revenue estimates remained unchanged at $450 billion to $455 billion, the midpoint of which would denote yearly growth of 6.8%. Also, UNH stock is trading at comfortable valuations. Its forward price-earnings ratio of 14.1x is nearly 40% below the sector median. The company will report its Q2 2025 earnings on July 29. Analyst Opinions on UNH Stock Overall, analysts have attributed a rating of 'Moderate Buy' for UnitedHealth stock, with a mean target price of $358.70. This denotes uspide potential of about 27% from current levels. Out of 24 analysts covering the stock, 15 have a 'Strong Buy' rating, two have a 'Moderate Buy' rating, and seven have a 'Hold' rating. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
15 minutes ago
- Forbes
Cannabis Is An ‘Effective Treatment' For Chronic Pain, Study Finds
New research shows that medical cannabis is an effective treatment for chronic and improves the ... More quality of life for patients who use it. The use of medical cannabis is an 'effective treatment option' for chronic pain patients, according to the findings of a recent study. The research also found that chronic pain patients who used cannabis for at least on year 'exhibited significantly lower healthcare utilization' than non-users and had better quality of life. The study, which was published last week in the journal Pharmacy, was written by researchers with the Florida-based medical cannabis telehealth company Leafwell and George Mason University in Virginia. The findings also showed that chronic pain patients who used cannabis reported fewer visits to urgent care centers and hospital emergency departments (EDs). Additionally, the data showed that hospitalization rates were lower among chronic pain patients who used medical marijuana, although the difference was not sufficient to be considered statistically significant. 'Exposure [to cannabis] was associated with a 2.0 percentage point reduction in urgent care visits, a 3.2 percentage point reduction in ED visits and fewer unhealthy days per month,' according to a report from online cannabis news source Marijuana Moment. 'The findings of this study suggest, in line with existing research, that medical cannabis is likely an effective treatment option for patients with chronic pain,' authors wrote. 'This underscores the potential for not only [quality of life] The self-reported data used for the study was collected from chronic pain patients by Leafwell. The telehealth platform operates in 36 states, connecting physicians with patients seeking certification to use medical cannabis. 'The cannabis-exposed group included individuals who had used medical cannabis within the prior year and were seeking recertification of their medical card through Leafwell,' the authors wrote, 'while the unexposed group comprised first-time Leafwell patients who self-reported no cannabis use in the past year.' Study Of More Than 5,000 Chronic Pain Patients The study included data from 5,242 chronic pain patients. Of them, 3,943 reported using cannabis over the past year, while the remaining 1,299 participants reported no past-year cannabis use. Mitchell Doucette, senior research director at Leafwell and the lead author of the study, said the findings show that medical cannabis can improve the lives of chronic pain patients. 'We looked at a large set of real-world data, where we compared medical cannabis users who we knew used for at least one year and people who had never used cannabis,' Doucette told Marijuana Moment. 'When we compared those groups, we found that medical cannabis users who had used for at least one year had lower rates of emergency room visits, lower rates of urgent care visits and, importantly, increased quality of life.' 'When we combine those outcomes,' added Doucette, who has a doctorate in health and public policy from Johns Hopkins, 'it suggests that medical cannabis is not only leading to better quality of life for chronic pain patients but, again, potentially better health outcomes.' Doucette noted that some previous studies have explored quality-of-life improvements among medical cannabis patients, and other research has studied healthcare outcomes, 'but really this is the first study to kind of connect these two dots.' Overall, Doucette said, it is becoming increasingly apparent that medical marijuana 'is a helpful medicinal product for certain groups of people' and that healthcare systems 'should try to alleviate access and cost margins for those individuals who it may be too costly of a product for them to access.' Cannabis And Chronic Pain The Leafwell study is consistent with other research into the use of medical cannabis as a treatment for chronic pain. Also last week, the National Organization for the Reform of Marijuana Laws (NORML) reported on the results of German study showing that cannabis extracts significantly reduced pain and improved mental health for chronic pain patients who used it. 'Our findings indicate that treatment with medicinal cannabis improves both physical and mental health in patients with chronic pain,' the study's authors concluded. 'The results suggest that medicinal cannabis might be a safe alternative for patients who are inadequately treated with conventional therapies.'
New York Times
17 minutes ago
- New York Times
Sanitariums and Stigma: When TB Was Common in the U.S.
Recently, the writer John Green spoke with The New York Times about his best-selling book 'Everything Is Tuberculosis' and the reason he developed an obsessive interest in the disease, which kills more people worldwide than any other infectious illness does. Tuberculosis has been rare in the United States for decades, but the conversation inspired many readers to write in to share their own families' history with the disease. Here are excerpts from several. My mother, Babe, had TB in the early 1930s and was put in the Grasslands sanitarium in Valhalla, N.Y. She survived because her doctor gave her pneumothorax treatment, collapsing one lung at a time, to let the lung rest and repair. She said it was very painful. I was told the story over and over. She was so afraid I would get TB. One reason she lived is because she had met my father, Grant, on a trip to California and fallen in love. He wrote to her everyday and even said he would go east, climb the walls of the sanitarium and take her to the clean air of the mountains in California so she could get well. Grant was a writer and a stuntman in Hollywood. He had been Errol Flynn's double in 'Robin Hood.' So he really meant it when he said he'd climb the walls to get her out. He didn't do that. But when Babe recovered, she took a train to California and married my father. Babe's doctor was Dr. William Godfrey Childress, whom I have since found out was one of the well-known TB experts in those days. I met him when she went in for a checkup many years later. (I was born when Babe was 44!) — Wyn Lydecker My grandfather, who immigrated from Ukraine, died at 38 from spinal TB. He left a wife and four children, and one of them, my uncle Walter, had spinal TB that left him about 5 feet tall with a hump. My father was drafted into World War II and came back to the United States and got TB. His brother Walter paid for him to be in a sanitarium called Gaylord in Connecticut. He met my mother there and she had TB, and after two years in the san, as it was called, antibiotics were invented. My mother could take them, but my father couldn't and had to have pneumothorax for many years. It was awful, and I am terrified about the resurgence of antibiotic-resistant TB. — Jody Jarowey I'm a retired M.D.-Ph.D. and I trained at Washington University in St. Louis from 1974 to 1981. In 1980, I took the admission history for a child being admitted for a lymph node biopsy. I'm sure everyone expected cancer. As a medical student, I did a very thorough history, asking about medications (none), whether the girl was up to date on her immunizations, and whether she'd had a TB test. Her mother said 'yes.' For some reason I asked whether the TB test was positive or negative, and she then told me 'positive' and 'Oh, yes, she's on a drug for that.' But the girl was growing, the dose hadn't been changed, and the child's uncle was on two drugs for drug-resistant TB. The multiple nodes in her neck? I can't say for sure, but the surgeons canceled the surgery when they learned of the TB. We had been doing the admission interview in the children's playroom on the pediatric ward. During my training I knew a fellow resident who was diagnosed with a pleural effusion. Surprise — the effusion was from TB! As a college student I worked in the genetics building on the University of Wisconsin campus. One day everyone was told we were going to get skin tests for TB, as someone working in the building had active TB. We don't think about TB much in the United States, but it's still here, and still killing people. The ignorance and the cruelty in our neglect of public health is shocking to me. Now we have left the W.H.O. and shut down U.S.A.I.D. It's hard to believe we are the same people who wiped out smallpox. — Laura J. Brown When I was 14, a small spot was found in my right lung, and I was treated for TB in a sanitarium in Ottawa, Ill. By state law, I had to be there for six months. The horror of this was that I was never actively contagious. I never coughed once, and no bacillus was ever found in my sputum or in the gastric lavages I underwent when they couldn't find TB in the sputum. The rules of the sanitarium were based on protocols developed at the end of the 19th century, long before the modern drugs I was treated with were discovered. — Sandy Robertson
